Resveratrol exerts antidepressant properties in the chronic unpredictable mild stress model through the regulation of oxidative stress and mTOR pathway in the rat hippocampus and prefrontal cortex

Behavioural Brain Research

Volumn 302, Issue , 2016, Pages 191-199

  liu, Song ^a   Li, Tong ^a,b   Liu, Hansen ^a   Wang, Xueer ^a   bo, Shishi ^a   Xie, Yunkai ^a   Bai, Xuemei ^a   Wu, Lin ^a   Wang, Zhen ^a   Liu, Dexiang ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Akt; Chronic unpredictable mild stress (CUMS); Depression; mTOR; Resveratrol

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RESVERATROL; SUPEROXIDE DISMUTASE; ANTIDEPRESSANT AGENT; MTOR PROTEIN, RAT; STILBENE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; FORCED SWIM TEST; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SUCROSE PREFERENCE TEST; ANIMAL; BRAIN; CHRONIC DISEASE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; FOOD PREFERENCE; LOCOMOTION; MENTAL STRESS; METABOLISM; PATHOLOGY; PSYCHOLOGY; SIGNAL TRANSDUCTION; SWIMMING; TIME FACTOR; WISTAR RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; CHRONIC DISEASE; DEPRESSION; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FOOD PREFERENCES; LIPID PEROXIDATION; LOCOMOTION; MALE; OXIDATIVE STRESS; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; STILBENES; STRESS, PSYCHOLOGICAL; SWIMMING; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84955508847     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2016.01.037     Document Type: Article

References (48)

1. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl.) 1997, 134:319-329.
2. Michel T.M., Frangou S., Thiemeyer D., Camara S., Jecel J., Nara K., et al. Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder-a postmortem study. Psychiatry Res. 2007, 151:145-150.
3. Chandran A., Iyo A.H., Jernigan C.S., Legutko B., Austin M.C., Karolewicz B. Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2013, 40:240-245.
4. Lucca G., Comim C.M., Valvassori S.S., Reus G.Z., Vuolo F., Petronilho F., et al. Effects of chronic mild stress on the oxidative parameters in the rat brain. Neurochemistry international. 2009, 54:358-362.
5. Jernigan C.S., Goswami D.B., Austin M.C., Iyo A.H., Chandran A., Stockmeier C.A., et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2011, 35:1774-1779.
6. Lu Y., Wang C., Xue Z., Li C., Zhang J., Zhao X., et al. PI3K/AKT/mTOR signaling-mediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13. Int. J. Neuropsychopharmacol. 2014, 18.
7. Zhong P., Wang W., Pan B., Liu X., Zhang Z., Long J.Z., et al. Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling. Neuropsychopharmacology 2014, 39:1763-1776.
8. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (New York, NY) 2010, 329:959-964.
9. Akinfiresoye L., Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology 2013, 230:291-298.
10. Juan M.E., Alfaras I., Planas J.M. Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol. Res. 2012, 65:584-591.
11. Zhang F., Liu J., Shi J.S. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur. J. Pharmacol. 2010, 636:1-7.
12. Orsu P., Murthy B.V., Akula A. Cerebroprotective potential of resveratrol through anti-oxidant and anti-inflammatory mechanisms in rats. J. Neural Transm. 2013.
13. Tome-Carneiro J., Larrosa M., Yanez-Gascon M.J., Davalos A., Gil-Zamorano J., Gonzalvez M., et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol. Res. 2013, 72:69-82.
14. Pallas M., Ortuno-Sahagun D., Benito-Andres P., Ponce-Regalado M.D., Rojas-Mayorquin A.E. Resveratrol in epilepsy: preventive or treatment opportunities?. Front. Biosci. (Landmark Ed.) 2014, 19:1057-1064.
15. Vingtdeux V., Giliberto L., Zhao H., Chandakkar P., Wu Q., Simon J.E., et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J. Biol. Chem. 2010, 285:9100-9113.
16. Zhao H.F., Li N., Wang Q., Cheng X.J., Li X.M., Liu T.T. Resveratrol decreases the insoluble Abeta1-42 level in hippocampus and protects the integrity of the blood-brain barrier in AD rats. Neuroscience 2015, 310:641-649.
17. Xu Y., Wang Z., You W., Zhang X., Li S., Barish P.A., et al. Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system. Eur. Neuropsychopharmacol. 2010, 20:405-413.
18. Yu Y., Wang R., Chen C., Du X., Ruan L., Sun J., et al. Antidepressant-like effect of trans-resveratrol in chronic stress model: Behavioral and neurochemical evidences. J. Psychiatric Res. 2013, 47:315-322.
19. Hurley L.L., Akinfiresoye L., Kalejaiye O., Tizabi Y. Antidepressant effects of resveratrol in an animal model of depression. Behav. Brain Res. 2014, 268:1-7.
20. Liu D., Xie K., Yang X., Gu J., Ge L., Wang X., et al. Resveratrol reverses the effects of chronic unpredictable mild stress on behavior, serum corticosterone levels and BDNF expression in rats. Behav. Brain Res. 2014, 264:9-16.
21. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59:1116-1127.
22. Duman R.S. Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. Dialogues Clin.Neurosci. 2014, 16:11-27.
23. Lupien S.J., Maheu F., Tu M., Fiocco A., Schramek T.E. The effects of stress and stress hormones on human cognition: Implications for the field of brain and cognition. Brain Cogn. 2007, 65:209-237.
24. Tang J., Xue W., Xia B., Ren L., Tao W., Chen C., et al. Involvement of normalized NMDA receptor and mTOR-related signaling in rapid antidepressant effects of Yueju and ketamine on chronically stressed mice. Sci. Rep. 2015, 5:13573.
25. 1H-MRS study in rats. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2014, 51:9-15.
26. Ducottet C., Griebel G., Belzung C. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2003, 27:625-631.
27. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 1987, 93:358-364.
28. Russo E., Citraro R., Davoli A., Gallelli L., Di Paola E.D., De Sarro G. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology 2013, 64:371-379.
29. Draper H.H., Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 1990, 186:421-431.
30. Wheeler C.R., Salzman J.A., Elsayed N.M., Omaye S.T., Korte D.W. Automated assays for superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activity. Anal. Biochem. 1990, 184:193-199.
31. Golden S.A., Christoffel D.J., Heshmati M., Hodes G.E., Magida J., Davis K., et al. Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nat. Med. 2013, 19:337-344.
32. Harro J., Tonissaar M., Eller M., Kask A., Oreland L. Chronic variable stress and partial 5-HT denervation by parachloroamphetamine treatment in the rat: effects on behavior and monoamine neurochemistry. Brain Res. 2001, 899:227-239.
33. Sarandol A., Sarandol E., Eker S.S., Erdinc S., Vatansever E., Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum. Psychopharmacol. 2007, 22:67-73.
34. Khanzode S.D., Dakhale G.N., Khanzode S.S., Saoji A., Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. 2003, 8:365-370.
35. Ahmad A., Rasheed N., Banu N., Palit G. Alterations in monoamine levels and oxidative systems in frontal cortex, striatum, and hippocampus of the rat brain during chronic unpredictable stress. Stress (Amsterdam, Netherlands) 2010, 13:355-364.
36. Che Y., Zhou Z., Shu Y., Zhai C., Zhu Y., Gong S., et al. Chronic unpredictable stress impairs endogenous antioxidant defense in rat brain. Neurosci. Lett. 2015, 584:208-213.
37. Rahman I., Biswas S.K., Kirkham P.A. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem. Pharmacol. 2006, 72:1439-1452.
38. Pervaiz S., Holme A.L. Resveratrol: its biologic targets and functional activity. Antioxid. Redox Signal. 2009, 11:2851-2897.
39. Mokni M., Elkahoui S., Limam F., Amri M., Aouani E. Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat. Neurochem. Res. 2007, 32:981-987.
40. Ren J., Fan C., Chen N., Huang J., Yang Q. Resveratrol pretreatment attenuates cerebral ischemic injury by upregulating expression of transcription factor Nrf2 and HO-1 in rats. Neurochem. Res. 2011, 36:2352-2362.
41. Chen C.Y., Jang J.H., Li M.H., Surh Y.J. Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem. Biophys. Res. Commun. 2005, 331:993-1000.
42. Hoeffer C.A., Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2010, 33:67-75.
43. Duman R.S., Li N., Liu R.J., Duric V., Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012, 62:35-41.
44. Newport D.J., Carpenter L.L., McDonald W.M., Potash J.B., Tohen M., Nemeroff C.B. Ketamine and other NMDA Antagonists: early clinical trials and possible mechanisms in depression. Am. J. Psychiatry 2015, 172:950-966.
45. Karege F., Perroud N., Burkhardt S., Schwald M., Ballmann E., La Harpe R., et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol. Psychiatry 2007, 61:240-245.
46. Dwivedi Y., Rizavi H.S., Zhang H., Roberts R.C., Conley R.R., Pandey G.N. Modulation in activation and expression of phosphatase and tensin homolog on chromosome ten, Akt1, and 3-phosphoinositide-dependent kinase 1: further evidence demonstrating altered phosphoinositide 3-kinase signaling in postmortem brain of suicide subjects. Biol. Psychiatry 2010, 67:1017-1025.
47. Machado-Vieira R., Zanetti M.V., Teixeira A.L., Uno M., Valiengo L.L., Soeiro-de-Souza M.G., et al. Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder. Eur. Neuropsychopharmacol. 2015, 25:468-473.
48. Krishnan V., Han M.H., Mazei-Robison M., Iniguez S.D., Ables J.L., Vialou V., et al. AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli. Biol. Psychiatry 2008, 64:691-700.